Category: Pharmaceuticals

Pharmaceuticals

Ivacaftor Safe in CF Infants Aged 1 to 4 Months

A phase 3 clinical trial, ivacaftor (Kalydeco, Vertex Pharma) was generally safe to administer to infants aged 1-month to <4-months old, according to research published in Journal of Cystic Fibrosis.

Pharmaceuticals

Boehringer Ingelheim Caps Patient Out-of-pocket Inhaler Costs at $35 per Month

Starting June 1, 2024, eligible patients will pay no more than $35 a month at retail pharmacies for all Boehringer Ingelheim inhalers, the company says.

Pharmaceuticals

FDA Approves Osimertinib plus Chemotherapy for EGFR-mutated NSCLC

The FDA approved osimertinib (Tagrisso) with platinum-based chemotherapy for certain patients with non-small cell lung cancer (NSCLC).

Clinical Trials

AstraZeneca’s NSCLC Therapy Imfinzi Misses Primary Endpoint in Ph3 Study

AstraZeneca's Imfinzi (durvalumab) concurrently administered with chemoradiotherapy did not achieve a Phase 3 primary endpoint of progression-free survival versus CRT alone for the treatment of patients with unresectable, Stage III non-small cell lung cancer.

US Pharmaceuticals

Preexisting Conditions May Elevate Heart Disorder Risk Post COVID-19 Vaccine

Cedars-Sinai investigators suggest it may be helpful to keep an eye on patients with underlying health issues after COVID-19 vaccination to monitor for post-vaccine POTS, a condition that causes an abnormal increase in heart rate after standing or sitting up.

Intl' Pharmaceuticals

Canada Approves Pfizer’s RSV Vaccine

The vaccine was approved for older adults and infants through maternal immunization.